InvaplexAR-Detox and dmLT Adjuvant in the Netherlands and Zambia

Conditions:   Shigellosis;   Bacillary Dysentery Interventions:   Biological: 2.5 μg InvaplexAR-Detox;   Biological: 2.5 μg InvaplexAR-Detox with 0.1 μg of dmLT;   Biological: 10 μg InvaplexAR-Detox;   Biological: 10 μg InvaplexAR-Detox with 0.1 μg of dmLT;   Biological: Placebo Sponsors:   Leiden University Medical Center;   Centre for Infectious Disease Research in Zambia;   PATH;   Walter Reed Army Institute of Research (WRAIR);   Göteborg University;   European Vaccine Initiative;   European and Developing Countries Clinical Trials Partnership (EDCTP) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials